Glofitamab in relapsed/refractory mantle cell lymphoma: Results from a phase I/II study

Authors

Tycel Jovelle Phillips, University of Michigan - Ann Arbor
Nancy L Bartlett, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Clinical Oncology

Publication Date

1-20-2025

Volume

43

Issue

3

First Page

318

Last Page

328

Document Type

Open Access Publication

DOI

10.1200/JCO.23.02470

Rights and Permissions

Phillips TJ, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trněný M, Bartlett NL, Zaucha J, Wrobel T, Offner F, Humphrey K, Relf J, Filézac de L'Etang A, Carlile DJ, Byrne B, Qayum N, Lundberg L, Dickinson M. Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. J Clin Oncol. 2025 Jan 20;43(3):318-328. doi: 10.1200/JCO.23.02470. © 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

Recommended Citation

Phillips, Tycel Jovelle; Bartlett, Nancy L; and et al., "Glofitamab in relapsed/refractory mantle cell lymphoma: Results from a phase I/II study." Journal of Clinical Oncology. 43, 3. 318 - 328. (2025).
https://digitalcommons.wustl.edu/oa_4/4683

Additional Links

Supplemental material is available for this article at publisher site.